Ameliogenix is developing AGXV Series, a pipeline of modular mRNA therapies that synergistically rewire cholesterol metabolism, offering tailored and personalized long-term control over lipid levels and reduced heart disease risk. Backed by a robust ecosystem including OBIO, MaRS, TIAP, Momentum AIR, Invest Ottawa, and FedDev, alongside academic partnerships with Carleton University and La Cite college, Ameliogenix is aggressively expanding its network to lead the next frontier of the mRNA therapeutics industry.